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This January issue of HPB represents the dawn of an era with a new team of publishers, Elsevier Ltd. We look forward 
to working with them and expect that there will be a seamless transition. During this time, we do not intend to introduce 
radical change to the format of the print journal other than an increase in the number of pages per issue. We hope that 
this expansion of the journal size will enable us to capture more high-quality manuscripts and ensure that each issue will 
have content attractive to the hepatobiliary and pancreatic surgeon, no matter how specialised! We look forward to your 
comments and feedback on how we can move the journal’s agenda forward in 2016.
Reports of individual case series often underestimate outcomes such as morbidity and mortality for any given 
procedure. For this reason, the report on total pancreatectomy for invasive carcinoma by Johnston and colleagues is 
most welcome in providing an improved perspective. The review of the National Cancer Database gives great insight into 
clinical practice in the USA demonstrating improvements in operative mortality over time. However, it documents the 
presence of advanced disease in a substantial number of patients operated on presumably with curative intent and resulting 
poor long-term outcomes. The systematic review of Zhou et al shows that the combination of pancreatic liver resection 
from biliary and gallbladder cancers, is associated with perioperative death in one of every 10 operated patients. No patient 
undergoing incomplete resection of tumour survived to 5 years. At the other end of the spectrum, Schneider and colleagues 
from Heidelberg reopen the debate as to whether surgical ampullectomy has a role in the management of ampullary lesions. 
For this surgical group, short-term outcomes were good and recurrence rates low. The trick for us lesser mortals will be to 
best determine which patients are likely to benefit from a lesser approach. It would seem that preoperative staging will be 
critical. Jung and colleagues suggest a role for PET-CT in detecting recurrence of resected pancreatic cancer even although 
we might not be too certain how we might use that information to extend life expectancy without compromising its quality! 
In patients with unresectable ampullary malignancy, Williamsson and colleagues demonstrated that good palliation could 
still be achieved with endoscopic placement of self-expanding metal stents. At the other end of the spectrum, De Rosa et 
al have reviewed the literature to clarify the indications for staging laparoscopy in patients with respectable pancreatic 
cancer. Some, like myself, have been proponents of laparoscopy and laparoscopic ultrasound staging of pancreatic cancer, 
but now advances in imaging have cast doubt on its value. This review of 24 studies suggests that if it is to be employed, 
laparoscopy will be most effective in patients with tumours greater than 3 cm in size and with elevated CA 19.9 levels.
Colleagues in the Netherlands have been at the forefront of studies in the management of pancreatic disease. An 
online survey from van Grinsven et al provides some evidence that the step-up approach to managing infected necrotising 
pancreatitis is most favoured although there seems poor agreement on the precise intervention and its timing. Similar 
issues arise when managing post-operative fluid collections following pancreatic resection. Tjaden et al systematically 
evaluated patients undergoing distal pancreatectomy in the post-operative period and demonstrated that such collections 
were frequent and normally of no clinical consequence. Only one in 10 patients required therapeutic intervention.
Teo et al provide collective evidence from a systematic review that Y90 SIRT results in significant hypertrophy of 
the contralateral liver lobe but many factors appear to impact on the rate of hypertrophy. It would normally be unusual 
for small case series to appear in HPB, but the report by Lee et al provides excellent illustration of how an investigative 
modality such as PET – CT can be adapted for use in evaluating benign liver pathology. Although useful interpretation of 
the data is limited, it seems to me that PET may have promise in avoiding unnecessary intervention.
Vilchez and colleagues interrogated the UNOS database to compare outcomes following liver transplantation 
in patients with hepatoma, cholangiocarcinoma or mixed tumours. As might be expected, those patients with 
cholangiocarcinoma as a component of their tumour faired worse but the challenge remains as how best to 
identify patients with such tumours prior to intervention. The debate as to whether resection or transplantation 
should be considered for hepatoma continues. Na et al make a case for down-staging HCC beyond Milan criteria 
before living donor liver transplantation and identifying factors that might better select patients for this approach. 
Kirichenko et al introduce the concept of stereotactic body radiotherapy as a safe and effective treatment for isolated 
inoperable hepatic malignancy whereas Koh et al suggest that ablation and embolization are equally effective in dealing 
with post-resection recurrence of hepatoma. 
Finally, in an analysis of the National Cancer Database, Jutric et al, confirm the poor outlook for patients with 
lymph node metastases in the surgical treatment of intrahepatic cholangiocarcinoma. The data have to be interpreted 
with caution, but there appears a beneficial place for adjuvant therapy and which is taken as suggesting a role for routine 
lymphadenectomy. These are all great articles with which to kick off 2016. We look forward to a steady stream of 
submissions in our International Congress year. myHPB is the perfect educational forum for specialist HPB surgeons and 
you should use this to start a conversation on any or all of this month’s content! 
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